2023
Improved Screening of Monoclonal Gammopathy Patients by MALDI-TOF Mass Spectrometry
PEČINKA, Lukáš, Monika VLACHOVÁ, Lukáš MORÁŇ, Jana GREGOROVÁ, Volodymyr POROKH et. al.Základní údaje
Originální název
Improved Screening of Monoclonal Gammopathy Patients by MALDI-TOF Mass Spectrometry
Autoři
PEČINKA, Lukáš (203 Česká republika, domácí), Monika VLACHOVÁ (203 Česká republika, domácí), Lukáš MORÁŇ (203 Česká republika, domácí), Jana GREGOROVÁ (203 Česká republika, domácí), Volodymyr POROKH (804 Ukrajina, domácí), Petra KOVAČOVICOVÁ (703 Slovensko, domácí), Martina ALMÁŠI (203 Česká republika), Luděk POUR (203 Česká republika), Martin ŠTORK (203 Česká republika), Josef HAVEL (203 Česká republika, domácí), Sabina ŠEVČÍKOVÁ (203 Česká republika, domácí) a Petr VAŇHARA (203 Česká republika, garant, domácí)
Vydání
Journal of the American Society for Mass Spectrometry, WASHINGTON, American Chemical Society, 2023, 1044-0305
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30400 3.4 Medical biotechnology
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 3.200 v roce 2022
Kód RIV
RIV/00216224:14110/23:00132350
Organizační jednotka
Lékařská fakulta
UT WoS
001123075900001
Klíčová slova anglicky
MALDI-TOF mass spectrometry; multiple myeloma; plasma cell leukemia; monoclonal gammopathy; principal component analysis; machine learning; partial least-squares-discriminant analysis; molecular profiling; fingerprinting
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 5. 11. 2024 16:04, Mgr. Pavla Foltynová, Ph.D.
Anotace
V originále
Monoclonal gammopathies are a group of blood diseases characterized by presence of abnormal immunoglobulins in peripheral blood and/or urine of patients. Multiple myeloma and plasma cell leukemia are monoclonal gammopathies with unclear etiology, caused by malignant transformation of bone marrow plasma cells. Mass spectrometry with matrix-assisted laser desorption/ionization and time-of-flight detection is commonly used for investigation of the peptidome and small proteome of blood plasma with high accuracy, robustness, and cost-effectivity. In addition, mass spectrometry coupled with advanced statistics can be used for molecular profiling, classification, and diagnosis of liquid biopsies and tissue specimens in various malignancies. Despite the fact there have been fully optimized protocols for mass spectrometry of normal blood plasma available for decades, in monoclonal gammopathy patients, the massive alterations of biophysical and biochemical parameters of peripheral blood plasma often limit the mass spectrometry measurements. In this paper, we present a new two-step extraction protocol and demonstrated the enhanced resolution and intensity (>50×) of mass spectra obtained from extracts of peripheral blood plasma from monoclonal gammopathy patients. When coupled with advanced statistics and machine learning, the mass spectra profiles enabled the direct identification, classification, and discrimination of multiple myeloma and plasma cell leukemia patients with high accuracy and precision. A model based on PLS-DA achieved the best performance with 71.5% accuracy (95% confidence interval, CI = 57.1–83.3%) when the 10× repeated 5-fold CV was performed. In summary, the two-step extraction protocol improved the analysis of monoclonal gammopathy peripheral blood plasma samples by mass spectrometry and provided a tool for addressing the complex molecular etiology of monoclonal gammopathies.
Návaznosti
| LX22NPO5102, projekt VaV |
| ||
| MUNI/A/1298/2022, interní kód MU |
| ||
| MUNI/A/1301/2022, interní kód MU |
| ||
| MUNI/A/1370/2022, interní kód MU |
| ||
| MUNI/A/1575/2023, interní kód MU |
| ||
| MUNI/11/ACC/3/2022, interní kód MU |
| ||
| NU21-03-00076, projekt VaV |
|
